CA3130735A1 - Inositol phosphate compounds for use in increasing tissular perfusion - Google Patents

Inositol phosphate compounds for use in increasing tissular perfusion Download PDF

Info

Publication number
CA3130735A1
CA3130735A1 CA3130735A CA3130735A CA3130735A1 CA 3130735 A1 CA3130735 A1 CA 3130735A1 CA 3130735 A CA3130735 A CA 3130735A CA 3130735 A CA3130735 A CA 3130735A CA 3130735 A1 CA3130735 A1 CA 3130735A1
Authority
CA
Canada
Prior art keywords
compound
formula
use according
subject
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3130735A
Other languages
English (en)
French (fr)
Inventor
Mohamad Firas BASSISSI
Carolina Salcedo Roca
Joan Perello Bestard
Miquel David Ferrer Reynes
Maria Del Mar Perez Ferrer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanifit Therapeutics SA
Original Assignee
Sanifit Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifit Therapeutics SA filed Critical Sanifit Therapeutics SA
Publication of CA3130735A1 publication Critical patent/CA3130735A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3130735A 2019-01-30 2020-01-30 Inositol phosphate compounds for use in increasing tissular perfusion Pending CA3130735A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19382061 2019-01-30
EP19382061.0 2019-01-30
US201962913259P 2019-10-10 2019-10-10
US62/913,259 2019-10-10
PCT/ES2020/070070 WO2020157362A1 (en) 2019-01-30 2020-01-30 Inositol phosphate compounds for use in increasing tissular perfusion

Publications (1)

Publication Number Publication Date
CA3130735A1 true CA3130735A1 (en) 2020-08-06

Family

ID=69770927

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3130735A Pending CA3130735A1 (en) 2019-01-30 2020-01-30 Inositol phosphate compounds for use in increasing tissular perfusion

Country Status (11)

Country Link
US (2) US20220000889A1 (enExample)
EP (1) EP3917535A1 (enExample)
JP (2) JP2022521119A (enExample)
KR (1) KR20210148078A (enExample)
CN (1) CN113365636A (enExample)
AU (1) AU2020213713B2 (enExample)
BR (1) BR112021014897A2 (enExample)
CA (1) CA3130735A1 (enExample)
IL (1) IL285084A (enExample)
MX (1) MX2021008966A (enExample)
WO (1) WO2020157362A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3199478A1 (en) * 2020-11-20 2022-05-27 Vifor (International) Ag Inositol hexakisphosphate analogues for treatment of calcification associated kidney diseases
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
EP0632720B1 (en) 1992-03-25 1998-11-11 Depomed Systems, Inc. Hydroxyethylcellulose-based sustained-release oral drug dosage froms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
AU6912500A (en) * 1999-08-25 2001-03-19 Gmp Companies, Inc. Enhanced oxygen delivery in mammals, methods and reagents related thereto
WO2001024830A2 (en) * 1999-10-05 2001-04-12 Theramed, Inc. Incorporation of chemical substances into cells
JP2004510687A (ja) 1999-11-02 2004-04-08 ディポメド，インコーポレイティド 胃への薬剤投与の強化のための供給モードの薬理学的誘導
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
AU2001281071A1 (en) * 2000-08-01 2002-02-13 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
AU2001279118A1 (en) * 2000-08-01 2002-02-13 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP3678144B2 (ja) 2000-12-22 2005-08-03 ウシオ電機株式会社 フィルム回路基板の周辺露光装置
JP2004532259A (ja) 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
US9358243B2 (en) 2011-09-29 2016-06-07 Eth Zurich Pharmaceutical compounds for use in the therapy of Clostridium difficile infection
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
US10624909B2 (en) * 2015-12-11 2020-04-21 Eth Zurich Inositol derivatives for use in pathological crystallization
CN108368137B (zh) 2015-12-11 2020-11-13 苏黎世联邦理工学院 用于艰难梭状芽胞杆菌感染的4,6-二(邻硫代磷酸盐)-肌醇-1,2,3,5-四-邻硫酸盐

Also Published As

Publication number Publication date
CN113365636A (zh) 2021-09-07
BR112021014897A2 (pt) 2021-09-28
AU2020213713A1 (en) 2021-07-22
EP3917535A1 (en) 2021-12-08
WO2020157362A1 (en) 2020-08-06
AU2020213713B2 (en) 2025-08-21
JP2024175025A (ja) 2024-12-17
JP2022521119A (ja) 2022-04-06
US20220000889A1 (en) 2022-01-06
MX2021008966A (es) 2021-11-04
IL285084A (en) 2021-09-30
US20230248749A1 (en) 2023-08-10
KR20210148078A (ko) 2021-12-07

Similar Documents

Publication Publication Date Title
JP7033642B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
JP2016512821A (ja) ヘモグロビンの修飾のための組成物及び方法
JP2024175025A (ja) 組織の灌流の増加における使用のためのイノシトールリン酸化合物
US6610702B2 (en) Ammonium salts of inositol hexaphosphate, and uses thereof
US20250295676A1 (en) Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
US9713597B2 (en) Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone
RU2838908C2 (ru) Соединения инозитолфосфата для применения для увеличения тканевой перфузии
HK40051461A (en) Inositol phosphate compounds for use in increasing tissular perfusion
RU2832087C1 (ru) Соединения инозитолфосфата для применения в лечении, замедлении прогрессирования или предупреждении сердечно-сосудистой кальцификации
US20230333087A1 (en) Methods for monitoring patient response to treatment of retinal oxidative diseases
JP2021502328A (ja) 筋ジストロフィーを治療するためのエダサロネキセント投与計画
JP2023141229A (ja) 高リン血症治療用医薬用組成物
US20220031690A1 (en) Anti-neurodegenerative disease agent

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240126